ZA200206879B - Fusion protein having enhanced in vivo erythropoietin activity. - Google Patents
Fusion protein having enhanced in vivo erythropoietin activity.Info
- Publication number
- ZA200206879B ZA200206879B ZA200206879A ZA200206879A ZA200206879B ZA 200206879 B ZA200206879 B ZA 200206879B ZA 200206879 A ZA200206879 A ZA 200206879A ZA 200206879 A ZA200206879 A ZA 200206879A ZA 200206879 B ZA200206879 B ZA 200206879B
- Authority
- ZA
- South Africa
- Prior art keywords
- fusion protein
- epo
- enhanced
- erythropoietin activity
- activity
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title abstract 4
- 108090000394 Erythropoietin Proteins 0.000 title abstract 4
- 229940105423 erythropoietin Drugs 0.000 title abstract 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 3
- 238000001727 in vivo Methods 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 abstract 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 abstract 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 abstract 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 abstract 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 abstract 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000044890 human EPO Human genes 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0075994A KR100467751B1 (ko) | 2001-12-03 | 2001-12-03 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200206879B true ZA200206879B (en) | 2003-04-29 |
Family
ID=36123483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200206879A ZA200206879B (en) | 2001-12-03 | 2002-08-28 | Fusion protein having enhanced in vivo erythropoietin activity. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7091326B2 (fr) |
| EP (1) | EP1316561B1 (fr) |
| JP (1) | JP4035400B2 (fr) |
| KR (1) | KR100467751B1 (fr) |
| CN (1) | CN100400548C (fr) |
| AT (1) | ATE352565T1 (fr) |
| AU (1) | AU2002300734B2 (fr) |
| BR (1) | BR0203386A (fr) |
| CA (1) | CA2400908C (fr) |
| DE (1) | DE60217804T2 (fr) |
| ES (1) | ES2280487T3 (fr) |
| MX (1) | MXPA02008454A (fr) |
| NZ (1) | NZ520776A (fr) |
| RU (1) | RU2232192C2 (fr) |
| TW (1) | TWI243827B (fr) |
| WO (1) | WO2003048210A1 (fr) |
| ZA (1) | ZA200206879B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| BRPI0414887A (pt) * | 2003-09-29 | 2006-12-12 | Warren Pharmaceuticals Inc E T | métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica |
| CN100516225C (zh) * | 2004-07-30 | 2009-07-22 | 成都地奥制药集团有限公司 | 人血清蛋白与促红细胞生成素的融合蛋白 |
| KR20200072568A (ko) * | 2005-08-05 | 2020-06-22 | 아라임 파마슈티칼즈, 인크. | 조직 보호 펩티드 및 이의 용도 |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| WO2007092252A2 (fr) * | 2006-02-03 | 2007-08-16 | Modigene Inc | Polypeptides a action prolongee et leurs procedes de production |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| CN100436482C (zh) * | 2006-04-14 | 2008-11-26 | 东莞太力生物工程有限公司 | 长效人促红细胞生成素融合蛋白及其制备和纯化方法 |
| WO2009012600A1 (fr) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Protéines de fusion |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| CN102994547B (zh) * | 2011-09-08 | 2015-05-13 | 哈药集团技术中心 | 重组人促红素-ctp融合蛋白生产工艺及应用 |
| CN103182073A (zh) * | 2011-12-29 | 2013-07-03 | 哈药集团技术中心 | 一种重组人干扰素α-CTP融合蛋白的药物注射剂 |
| EP2838552A4 (fr) | 2012-04-19 | 2016-05-18 | Opko Biolog Ltd | Variants d'oxyntomoduline à action prolongée et procédés pour les produire |
| SG10202010383YA (en) * | 2012-11-20 | 2020-11-27 | Opko Biologics Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
| WO2014159813A1 (fr) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Molécules polynucléotidiques à longue durée de vie |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| PE20171380A1 (es) * | 2014-12-10 | 2017-09-15 | Opko Biologics Ltd | Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada |
| WO2016203482A2 (fr) | 2015-06-19 | 2016-12-22 | Opko Biologics Ltd. | Facteurs de coagulation à action prolongée et leurs procédés de production |
| CA3030533A1 (fr) | 2016-07-11 | 2018-01-18 | Oren HERSHKOVITZ | Facteur vii de coagulation a action prolongee et procedes de production associes |
| CN110393801A (zh) * | 2018-04-24 | 2019-11-01 | 中国科学院上海生命科学研究院 | 靶向促黄体生成素促进机体造血的应用 |
| CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6225449B1 (en) * | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
| AU648020B2 (en) * | 1989-02-21 | 1994-04-14 | Washington University | Modified forms of reproductive hormones |
| US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| ATE187740T1 (de) * | 1993-04-20 | 2000-01-15 | Univ Washington | Modifizierte proteine und peptide enthaltende pharmazeutische mittel |
| ZA946122B (en) * | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| AU782496B2 (en) | 1999-07-13 | 2005-08-04 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
| EP1228214A2 (fr) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Formes d'erythropoietine dotees de proprietes ameliorees |
| DE60117919T2 (de) | 2000-12-11 | 2006-12-14 | Cheil Jedang Corp. | Fusionsprotein mit verbesserter in vivo erythropoietinwirkung |
-
2001
- 2001-12-03 KR KR10-2001-0075994A patent/KR100467751B1/ko not_active IP Right Cessation
-
2002
- 2002-07-17 US US10/196,183 patent/US7091326B2/en not_active Expired - Lifetime
- 2002-08-06 WO PCT/KR2002/001493 patent/WO2003048210A1/fr active Search and Examination
- 2002-08-09 TW TW091117964A patent/TWI243827B/zh not_active IP Right Cessation
- 2002-08-13 AU AU2002300734A patent/AU2002300734B2/en not_active Ceased
- 2002-08-14 AT AT02255679T patent/ATE352565T1/de not_active IP Right Cessation
- 2002-08-14 DE DE60217804T patent/DE60217804T2/de not_active Expired - Lifetime
- 2002-08-14 ES ES02255679T patent/ES2280487T3/es not_active Expired - Lifetime
- 2002-08-14 EP EP02255679A patent/EP1316561B1/fr not_active Expired - Lifetime
- 2002-08-14 NZ NZ520776A patent/NZ520776A/en not_active IP Right Cessation
- 2002-08-26 BR BR0203386-0A patent/BR0203386A/pt not_active Application Discontinuation
- 2002-08-28 JP JP2002248825A patent/JP4035400B2/ja not_active Expired - Fee Related
- 2002-08-28 ZA ZA200206879A patent/ZA200206879B/xx unknown
- 2002-08-29 MX MXPA02008454A patent/MXPA02008454A/es active IP Right Grant
- 2002-08-29 CA CA2400908A patent/CA2400908C/fr not_active Expired - Fee Related
- 2002-08-29 RU RU2002123286/13A patent/RU2232192C2/ru not_active IP Right Cessation
- 2002-09-05 CN CNB021318832A patent/CN100400548C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE352565T1 (de) | 2007-02-15 |
| CN100400548C (zh) | 2008-07-09 |
| US7091326B2 (en) | 2006-08-15 |
| US20030113871A1 (en) | 2003-06-19 |
| AU2002300734B2 (en) | 2009-01-08 |
| CA2400908A1 (fr) | 2003-06-03 |
| KR100467751B1 (ko) | 2005-01-24 |
| EP1316561B1 (fr) | 2007-01-24 |
| KR20030045341A (ko) | 2003-06-11 |
| CA2400908C (fr) | 2011-04-12 |
| WO2003048210A1 (fr) | 2003-06-12 |
| CN1422870A (zh) | 2003-06-11 |
| NZ520776A (en) | 2004-02-27 |
| EP1316561A1 (fr) | 2003-06-04 |
| DE60217804T2 (de) | 2007-09-13 |
| ES2280487T3 (es) | 2007-09-16 |
| JP2003189853A (ja) | 2003-07-08 |
| DE60217804D1 (de) | 2007-03-15 |
| RU2232192C2 (ru) | 2004-07-10 |
| MXPA02008454A (es) | 2005-08-26 |
| TWI243827B (en) | 2005-11-21 |
| BR0203386A (pt) | 2004-05-25 |
| JP4035400B2 (ja) | 2008-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200206879B (en) | Fusion protein having enhanced in vivo erythropoietin activity. | |
| AU2002222740A1 (en) | Fusion protein having the enhanced in vivo activity of erythropoietin | |
| EP2557160A3 (fr) | D-aminotransférase mutée et procédé de production de dérivés dýacide glutamique optiquement actif lýutilisant | |
| NZ517012A (en) | Peptides that lower blood glucose levels | |
| CA2423887A1 (fr) | Desoxynucleotidyl-transferase terminale recombinante possedant une fonctionnalite superieure | |
| EP1449918A4 (fr) | Procede de production de l-aminoacides a l'aide d'escherichia | |
| HK1086296A1 (en) | Process for producing dipeptide | |
| SI1077692T1 (en) | Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same | |
| MXPA02005851A (es) | Formula para bebes con contenido proteinico mejorado. | |
| AU4063697A (en) | Methods for regulating gastrointestinal motility | |
| HK1026215A1 (en) | Analogs of parathyroid hormone | |
| RU2002123286A (ru) | Слитый белок с увеличенной эритропоэтиновой активностью, нуклеиновая кислота, кодирующая слитый белок, и способ получения слитого белка | |
| EP1319712A3 (fr) | Protéine de fusion ayant une activité d'erythropoietine améliorée | |
| MXPA04004848A (es) | Dispositivo para conectar un soporte longitudinal con un medio de fijacion osea. | |
| PL353085A1 (en) | Method of obtaining l-amino acids not forming any proteins | |
| WO2000069901A3 (fr) | Nouvelles proteines a action insulinoide utilisees dans le traitement du diabete | |
| NO20040751L (no) | Hvitt proteinglutenmel og fremgangsmate for andvendelse derav | |
| DK0427863T3 (da) | DNA, som koder for protein, som kan kombinere med forstærker for alfa-fetoprotein-gen | |
| SG109959A1 (en) | 5-substituted hydantoin recemase, dna coding for the same, recombinant dna, transformed cells, and process for producing optically active amino acids | |
| EE200000487A (et) | Kaspaas-8 proteaasiga interakteeruv proteiin, seda kodeeriv DNA järjestus, selle valmistamis- ja identifitseerimismeetod ning kasutamine ravimi valmistamiseks | |
| AU4964197A (en) | Recombinant single-stranded equine chorionic gonadotropin | |
| AU2001285178A1 (en) | Glut10: a novel glucose transporter in the type 2 diabetes linked region of chromosome 20q12-13.1 | |
| MXPA02002489A (es) | Analogos monomericos de insulina humana. | |
| ES2115543A1 (es) | Procedimiento para la obtencion de carbetocina y sus sales de adicion de acido farmaceuticamente aceptables o complejos de la misma. | |
| CA2285700A1 (fr) | Substance affichant une activite de la renine |